All In Biotech

Drug Trial Radar · NCT05208177

A Study of SHR-1802 in Patients With Advanced Solid Tumor

A Phase Ⅰb/Ⅱ Dose-exploration and Efficacy-expansion Study of SHR-1802 Combined With Camrelizumab for Injection and Famitinib Malate Capsules for the Treatment of Advanced Solid Tumor

Last checked: Nov 20, 2026Latest source record: Aug 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

25

Actual

Start

Apr 22, 2022

Primary completion

Aug 18, 2023

Study completion Aug 18, 2023

Sponsor

Sponsor type
Industry
First posted
Jan 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the safety and tolerability of SHR-1802 combined with camrelizumab and famitinib in subjects with advanced solid tumor and to determine the dose-limiting toxicity (DLT),recommended phase II dose (RP2D) and assess objective response rate (ORR) assessed by the investigator based on RECIST v1.1 criteria.

Conditions

  • Advanced Solid Tumor

Interventions

  • SHR-1802+camrelizumab + famitinibDrug

    SHR-1802 for injection,q3w; Camrelizumab for injection, q3w; Famitinib malate capsules, qd.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicity (DLT)Time frame: 4 weeks
  2. Recommended phase II dose (RP2D)Time frame: up to 1 years
  3. ORRTime frame: up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Medical University Cancer Institute&Hospital

    Tianjin, Tianjin Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.